drugset / Trial / NCT01634789

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789

Phase 1 Terminated 2 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate 3 test formulations relative to a reference formulation.

Timeline

Start
2012-08
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg Oral
Subject conjugated estrogens Other / unclassified 0.625 mg Oral

Indications

No indication recorded.